News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VBL Therapeutics Presents Two Studies on VB-111 at 102nd Annual American Association for Cancer Research Meeting


4/6/2011 11:15:59 AM

TEL AVIV, Israel & ORLANDO, Fla.--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111’s potential utility as a targeted cancer treatment. The company presented two studies, one demonstrating the safety and specificity of VB-111 and the other demonstrating its promise against glioblastoma, at the American Association for Cancer Research (AACR) 102nd Annual Meeting, taking place this week in Orlando, Fla.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES